<DOC>
	<DOC>NCT00624312</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of a two-dose regimen of Procrit prior to a major surgical oncology operation.</brief_summary>
	<brief_title>Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Undergoing a major surgical oncology procedure as defined below: Pancreatectomy Hepatectomy Esophagectomy Gastrectomy Retroperitoneal Sarcoma Resection 18 years of age and older Hemoglobin level of ≥ 10g/dL to &lt; 13g/dL, within 10 days of enrollment If female of childbearing potential, negative pregnancy test within 14 days prior to surgery If subject is a sexually active male or a sexually active female of child bearing potential, subject agrees to use a medically accepted form of contraception from the time of enrollment to completion of all followup study visits IRBapproved informed consent, signed by the subject or the subject's legally authorized representative ≥ 18 years of age Preoperative hemoglobin level ≥ 13g/dL or &lt; 10g/dL Uncontrolled hypertension (defined as a systolic pressure ≥ 160 and/or a diastolic pressure ≥ 110) History of allergy to Procrit® Known hypersensitivity to mammalian cellderived products or human albumin History of spontaneous venous thrombotic vascular events Anemia due to factors other than cancer,(e.g. iron deficiency, B12 deficiency) History of (within 12 months) deep venous thrombosis (DVT), pulmonary embolus (PE), or other venous thrombotic events. Prior superficial thrombophlebitis is not an exclusion criterion History of (within 6 months) uncontrolled cardiac arrhythmias, cerebrovascular accident (CVA), transient ischemic attack (TIA), acute coronary syndrome (ACS), or other arterial thrombosis. ACS includes Unstable Angina, Q wave Myocardial Infarction (QwMI), and nonQ wave myocardial infarction (NQMI) Currently receiving therapeutic or prophylactic anticoagulants for conditions other than planned surgery. The only exceptions are low dose aspirin (≤ 325 mg/day) or low dose anticoagulant to maintain patency of intravenous (IV) lines Patient is a candidate for autologous blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Procrit</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Patients undergoing major surgical oncology operations</keyword>
</DOC>